STERIS plc (Ireland)NYSE: STE
Health Care · Health Care Equipment
$209.32
+0.25%
Vol: 92K
Research Digest
Friday, June 19, 2026
STERIS reports record fiscal 2026 results with 9% revenue growth; KeyBanc cuts price target to $269 on peer multiple compression.
STERIS reported record fiscal year 2026 results featuring 9% revenue growth and 10% adjusted EPS growth across all segments, and issued fiscal 2027 guidance calling for 7-8% revenue growth and 9-11% EPS growth, with continued investment in automation, M&A, and share buybacks. KeyBanc analyst Brett Fishbin maintained an Overweight rating but lowered the price target to $269 (from $291) citing lower peer group multiples, while shares trade around $210. The Brooklyn Park, Minnesota lab added GLP-compliant cytotoxicity testing capacity in June, and a $0.63/share dividend went ex-dividend on June 8, 2026. An insider — SVP and General Counsel John Zangerle — sold 1,419 shares on June 15, 2026. The primary risk is multiple compression in medtech limiting near-term upside despite solid fundamental execution.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21STERIS posts record FY26 results with 9% revenue growth and authorizes new $1B share buybackMixed▶
STERIS reported Q4 FY26 EPS of $2.83 (missing $2.88 estimate) with revenue of $1.59B, while full-year revenue rose 9% to $5.9B and adjusted EPS climbed to $10.17. The Board authorized a fresh $1B share repurchase program replacing the prior authorization, alongside a $0.63 quarterly dividend. Management guided FY27 reported revenue growth of 7-8% and adjusted EPS of $11.10-$11.30. This signals durable procedure-volume tailwinds and continued capital returns. KeyBanc lowered its price target to $269 from $291 on May 13, indicating some analyst caution despite the buyback authorization.
May 20STERIS posts record FY26 results with $1B buyback authorization but KeyBanc cuts price target to $269Mixed▶
STERIS announced fiscal 2026 full-year revenue up 9% to $5.9B and adjusted EPS of $10.17, though Q4 EPS of $2.83 missed estimates of $2.88 and revenue of $1.588B missed $1.611B consensus. The Board authorized a new $1B share buyback program replacing prior authorization, and the company is investing in a new sterility assurance manufacturing plant in Mentor, Ohio, expected operational by late 2027. FY27 guidance calls for 7-8% reported revenue growth and adjusted EPS of $11.10-$11.30 (9-11% growth). The company declared a $0.63 quarterly dividend payable June 26. KeyBanc lowered its price target to $269 from $291 on May 13. Pierre Boulud was appointed to the board. Stock trades near $212.88.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18STERIS reported FY26 revenue up 9% to $5.9B with adjusted EPS of $10.17 and authorized a new $1 billion share buyback program on May 11.Positive▶
On May 11, 2026, STERIS reported fiscal 2026 Q4 and full-year results with revenue up 9% to $5.9B and adjusted EPS of $10.17, though Q4 EPS of $2.83 missed the $2.88 estimate. Q4 Healthcare revenue rose 7% to $1.14B, AST grew 6% to $289.2M, and Life Sciences grew 9% to $162.9M. The Board authorized a new $1 billion share buyback program, replacing the prior authorization. STERIS announced a strategic investment to build a new sterility assurance manufacturing plant in Mentor, Ohio, operational by late 2027. Fiscal 2027 guidance projects 7-8% revenue growth with adjusted EPS of $11.10-$11.30 (9-11% growth). STE was up 4.04% post-earnings. On May 7, Pierre Boulud was appointed to the Board; a $0.63 quarterly dividend was declared May 5.
May 15STERIS reported FY26 results with revenue up 9% to $5.9B and authorized a new $1B buyback, though Q4 EPS of $2.83 missed by $0.02 and KeyBanc cut its price target to $269 from $291.Mixed▶
On May 11, 2026, STERIS plc reported fiscal 2026 fourth-quarter and full-year results. FY26 revenue grew 9% to $5.9B and Q4 revenue rose 7% to $1.6B, but Q4 adjusted EPS of $2.83 missed by $0.02 triggering a ~2% premarket decline. The board authorized a new $1B share buyback replacing the prior plan and approved a $0.63 quarterly dividend. Pierre Boulud was appointed to the board effective May 5. FY27 guidance calls for adjusted EPS of $11.10-$11.30 (+9-11% vs $10.17) with ~$375M capex including a new sterility-assurance plant in Mentor, Ohio, targeted operational by late 2027. KeyBanc cut PT to $269 from $291 while keeping Buy. Shares traded near $214.70 on May 14. Risk: ongoing margin and capex absorption during plant build-out.
May 14STERIS posted 9% FY26 revenue growth to $5.9B on May 11, authorized $1B buyback and added bioMerieux CEO to boardPositive▶
On May 11, 2026, STERIS reported fiscal Q4 revenue of $1.59B (+7%) and full-year revenue of $5.9B (+9%) with adjusted EPS rising to $10.17. The Board authorized a new $1B share repurchase program and the company is investing $60M in a new sterility assurance plant in Mentor, Ohio (operational late 2027). FY27 guidance: revenue growth 7-8%, adjusted EPS $11.10-$11.30 (+9-11%). On May 7, STERIS appointed bioMerieux CEO Pierre Boulud to the Board. Quarterly dividend of $0.63 declared May 5. Stock rose 4.46% post-earnings on the strong outlook. Risk: Q4 revenue slightly below $1.61B consensus; healthcare capex sensitivity.
May 13STERIS reported FY2026 revenue up 9% to $5.9B, authorized a new $1B share buyback, and guided FY2027 adjusted EPS to $11.10-$11.30 (9-11% growth).Positive▶
STERIS announced FY2026 Q4 and full-year results on May 11, with Q4 revenue up 7% to $1.6B and full-year revenue up 9% to $5.9B (organic growth 7%). Diluted EPS from continuing operations rose to $7.93 and adjusted EPS to $10.17. The board authorized a new $1B buyback and plans a $60M sterility assurance plant in Mentor, Ohio. FY2027 guidance calls for 6-7% organic growth and adjusted EPS of $11.10-$11.30. The board appointed bioMérieux CEO Pierre Boulud as a director and declared a $0.63 quarterly dividend payable June 26.
May 12STERIS reported FY26 revenue +9% to $5.9B, authorized a new $1B buyback, and guided FY27 adjusted EPS to $11.10-$11.30 (+9-11%).Positive▶
STERIS plc on May 11, 2026 reported fiscal 2026 full-year revenue from continuing operations up 9% to $5.9B (7% constant-currency organic) and Q4 revenue +7% to $1.6B. Adjusted diluted EPS for FY26 was $10.17. FY27 guidance: revenue +7-8% (organic 6-7%) and adjusted EPS $11.10-$11.30, implying 9-11% growth. The board authorized a new $1B share buyback program and declared a $0.63 quarterly dividend on May 5. STERIS plans to invest ~$60M over two years to build a new sterility-assurance manufacturing plant in Mentor, Ohio. bioMérieux CEO Pierre Boulud was appointed to the Board. Tariff headwinds remain a flagged risk for margins.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| STESTERIS | $209.32 | +0.25% | +0.9% | 17.1x | 0.91 | $20.4B |
| ABTABBOTT | $103.88 | +0.18% | +0.7% | 17.1x | 0.59 | $179.4B |
| ISRGINTUITIVE | $398.38 | -0.92% | +0.1% | 33.3x | 1.47 | $144.1B |
| MDTMEDTRONIC | $90.13 | -0.71% | -1.1% | 14.2x | 0.57 | $116.1B |
| SYKSTRYKER | $273.51 | -0.57% | +0.3% | 16.4x | 0.77 | $105.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.